Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Landmark Series A Funding Propels Psychedelic Therapy Developer
A Promising Chapter for Psychedelic Therapy Emerging from the crucible of skepticism, MAPS Public Benefit Corporation, an offshoot of the Multidisciplinary Association for Psychedelic Studies, has defied convention and secured over $100 million in a game-changing Series A private stock sale. This substantial injection of capital will fortify the final stages of its pursuit to ...











